Evogene Posts 31 Percent Q3 Revenue Growth | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evogene today reported a 31 percent revenue spike for the third quarter ended Sept. 30.

The Rehovot, Israel-based plant genomics firm reported total revenues of $3.4 million for the quarter compared to $2.6 million for the third quarter of 2010.

Evogene's net loss for the quarter was $2.3 million, or $.07 per share, versus a loss of $3.6 million, or $.12 per share, for the third quarter of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.